Double-Blind Placebo Controlled Study of Thiamine and Cognitive Effect on Chronic Hemodialysis Patients

Isolda Prado de Negreiros Nogueira Maduro1*, Siane Prado Lima Souza2, Alba Regina Jorge Brandão3 and Karla Cristina Petruccelli Israel4

1Department of Nutrition, Amazonas State University, Brazil
2Department of Neurology, Hospital Universitário Getúlio Vargas, Brazil
3Department of Nephrology, Centro de Doenças Renais do Estado do Amazonas, Brazil

Abstract

Introduction: This study proposed to assess cognitive function against the use of thiamine vs. placebo in patients undergoing Chronic Hemodialysis (CHD) because this group commonly presents risks of losses of vitamins and other nutrients related to dialysis procedure.

Methods: In a double-blind study, 32 patients (12 female/16 male, 55.8 ± 10.10 years) submitted to CHD were recruited underwent collection of blood lactate (changed values above 2.0 mMol/L), Mini-Mental State Exam (MMSE) (changed values score 24 points). Patients were randomly divided into four groups receiving thiamine 300 mg, thiamine 600 mg, placebo and control (no vitamin or placebo), during one month. Excluding those using multivitamins, thiamine or cholinergic replacement therapy, patients with respiratory failure, acute coronary insufficiency, unconscious, pregnancy, and indigenous ethnicity, younger than 18 years. Blood lactate and MMSE were assessed before and after the study.

Findings: Thiamine supplementation (300 mg or 600 mg) during one month did not interfere with MMSE in groups or within groups. Groups before vs. after: control group 27.6 ± 1.6 vs. 27.7 ± 1.9 (ns); placebo group 26.7 ± 1.8 vs. 27.0 ± 1.7 (ns); thiamine 300 mg group 27.3 ± 1.1 vs. 27.8 ± 1.6 (ns), thiamine 600 mg group 26.4 ± 1.0 vs. 26.8 ± 1.3 (ns). Moreover, lactate values were not altered during the study.

Discussion: The results suggest no cognitive interfere for patients on chronic hemodialysis with 300 mg or 600 mg of thiamine for 1 month compared with placebo or control groups. Studies with longer duration or the active form of the vitamin should be tested further.

Keywords: Thiamine; Dialysis; Mini-mental; Cognition; Lactate

Introduction

Thiamine (or Vitamin B1) is an essential compound in metabolic reactions indispensable for the maintenance of a healthy life. As a water soluble vitamin, thiamine is absorbed through diffusion and active transport at the jejunum and the ileum, where it is metabolized by phosphorylation at the intestinal wall into thiamine pyrophosphate, its active form and co-factor to important enzymatic complexes [1]. Thiamine deficiency has four classic presentations: Painful (or painless) peripheral motor-sensitive polyneuropathy, affecting mainly the distal limbs (dry beriberi); sodium retention, vasodilation and water retention, resulting in high cardiac output, edema and bilateral ventricular dysfunction (chronic wet beriberi); acute wet beriberi, associated to myocardial lesion and circulatory shock (Shoshin-beriberi) and Wernicke encephalopathy, characterized by ataxia, motor ocular dysfunction, mental confusion, amnesia, learning disability and confabulation (Korsakoff’s encephalopathy) [2].

These clinical manifestations are frequently noticed in populations which main dietary component is cassava or its flour, polished or grounded rice, and wheat flour, therefore thiamine poor food [3]. Another important cause of thiamine deficiency occurs in chronic conditions as for End Stage Renal Disease (ESRD) patients undergoing Renal Replacement Therapy (RRT) [4]. Malnutrition is a common feature in ESRD patients for a number of reasons: anorexia, inadequate diet, hypercatabolism, protein-energy wasting, and loss of nutrients through dialysis membranes (particularly amino acids and water-soluble vitamins), chronic inflammation, dialysis inadequacy.
and bioincompatible membranes [5-8].

The purpose of the present double-blind study was to evaluate the cognitive responses of daily oral thiamine supplementations on 300 mg and 600 mg doses when compared to placebo, in a group of patients who do not necessarily have cognitive impairment, who were enrolled on regularly chronic dialysis program and not yet have been received vitamin supplementation, as this group is at high risk of vitamin losses and nutritional deficiency related to RRT. Thus, the aim of the study would be to verify the impact of thiamine supplementation in two different doses, using the mini-mental state examination, a “popular” tool to assess cognitive status. In addition, our study also sought to verify indirect measures of serum thiamine increase (serum lactate decrease) [9].

Materials and Methods

Patient enrollment

A double-blind prospective study was conducted on patients recruited at the Centro de Doenças Renais do Estado do Amazonas (CDR). The Research Ethics Committee of Amazonas State University, Amazonas, Brazil, approved the study and the patients gave written informed consent to participate. Inclusion criteria were: Patients who had been on CHD for at least 6 months, older than 18 years, with no upper age limit; using a biocompatible Hemodialysis (HD) membrane (Fresenius Medical Care”, F5, F6, F7 or F8, Germany), with Kt/V 1.3, and who were on a thrice-weekly low-flux HD program. Active infectious disease, cancer, respiratory failure, acute coronary insufficiency, unconsciousness, pregnancy, use of steroids, thiamine in similar doses or cholinergic replacement therapy, previous adverse effects on thiamine supplementation, indigenous ethnicity, were exclusion criteria. The patients were allowed to keep up with their usual multivitamin supplements since these had lower doses of thiamine if compared to those prescribed on the study. The present protocol did not interfere with any medical routine.

Experimental design

Thirty-two patients who voluntarily participated in the study were first selected by clinical evaluation and maintained on their respective dialysis shift routine. The patients had their cognitive status initially evaluated through the Mini-Mental State Examination (MMSE). MMSE is divided in seven parts, including temporal orientation, spatial perception, recent memory, calculus, attention, evocation, language and visual construction. The researchers used a version of MMSE validated for Brazilian patients [10,11]. The cut-off was 24 points for individuals with more than 8 school years and 17 points for patients with less than 8 school years (scores at MMSE vary from 0 to 30 points). After the MEEM, patients were randomly selected by clinical evaluation and maintained on their usual multivitamin supplements since these had lower doses of thiamine if compared to those prescribed on the study. The present protocol did not interfere with any medical routine.

Results and Discussion

Twenty-eight patients (of 32 recruited) completed the study, divided in four groups of seven components. There were 12 women and 16 men, ages varying between 37 and 74 years old (55.78 ± 10.11), with no significant difference between groups regarding their demographic aspects, beside the variation of patients ages between groups. No major clinical events were observed during dialytic therapy throughout the study.

As for the nutritional status of the study groups, we found a mean BASAL BMI of 22.64 kg/m^2 ± 3.26 kg/m^2, with 14.28% of the patients where underweight (BMI<18.5 kg/m^2); 17.85% were overweight and 67.85% were eutrophic (p<0.05). There was no difference regarding the anthropometric data between the beginning and the end of the study.

The blood levels of lactate were similar and stable in all groups, with no significant differences between the stages of the study, as shown in Table 2.

Thiamine deficiency can lead to peripheral nerve degeneration. In some occasions, it may result in brain damage, some of Table 1: Comparison of the MMSE punctuations between the groups, at the beginning and the end of the study.

<table>
<thead>
<tr>
<th>Groups</th>
<th>AGE Year</th>
<th>BASAL MMSE score</th>
<th>FINAL MMSE score</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I Thiamine 300 mg</td>
<td>55.4 ± 10.8</td>
<td>27.3 ± 1.1</td>
<td>27.8 ± 1.6</td>
<td>ns</td>
</tr>
<tr>
<td>Group II Thiamine 600 mg</td>
<td>58.8 ± 7.9</td>
<td>26.4 ± 1.0</td>
<td>26.8 ± 1.3</td>
<td>ns</td>
</tr>
<tr>
<td>Group III Placebo</td>
<td>51.4 ± 12.9</td>
<td>26.7 ± 1.8</td>
<td>27.0 ± 1.73</td>
<td>ns</td>
</tr>
<tr>
<td>Group IV Control</td>
<td>57.4 ± 8.6</td>
<td>27.6 ± 1.6</td>
<td>27.7 ± 1.9</td>
<td>ns</td>
</tr>
</tbody>
</table>

p-value: P<0.05 Group II vs. Group III

MMSE: Mini-Mental State Examination
Remedy Publications LLC. 3 2020 | Volume 3 | Issue 1 | Article 1006

irreversible nature as in dry Beriberi and in Wernicke-Korsakov’s Syndrome, where myelinic degeneration leads to symptoms that may decrease with treatment but generally rebound a short time after, because thiamine supplementation does not cure established lesions, it only prevents further demyelination [13]. The present study was developed in a group of chronic dialysis patients, at risk of nutrient loss [14]. There is a well-established relation between thiamine deficiency and impaired cognitive function. The hypothesis made was that losses of thiamine in the dialysate could result in a cognitive deficit, detectable through the chosen analysis instrument, MMSE. Thus, the blinded test of thiamine supplementation would alter the scores in the test. So, we assessed the mental status of the four groups of patients through MMSE. The groups were randomly assigned to receive pills similar in weight, but with different compositions (300 mg of thiamine, 600 mg of thiamine and 600 mg of starch). There was also a group which was assigned to receive no pills, control group.

In the present study, as reported previously by our group [6], around 14% of the CHD patients showed signs of malnutrition, like BMI below 18.5 kg/m². The data specific for the patients in RRT, however, demands a BMI over 23 kg/m² to exclude cachexia and muscular wasting due to the dialysis procedure [15]. Both malnutrition and cachexia may occur by low protein-energy ingestion, as a consequence of reduced assimilation or utilization of nutrients or due to hyper catabolism and systemic inflammation, highly prevalent amongst ESRD patients, even at the start of RRT [16].

Thus, 50% of the patients enrolled in this study were under this cutoff point, although there was no difference between groups I and II even after thiamine supplementation. Since thiamine deficiency can lead to anorexia, supplementation could lead to appetite increased, with gain in weight following supplementation. Unfortunately, due to the brevity of the supplementation we did not observe the weight gain [17,18].

The relation of high blood lactate levels and low total thiamine blood levels are well documented [9], which is directly linked to important step of glucose aerobic metabolism. As coenzyme thiamine pyrophosphate, this vitamin acts together with pyruvate dehydrogenase, an enzymatic complex responsible for pyruvate oxidative decarboxylation and consequent formation of acetyl Coenzyme A (acyt-CoA). This vitamin deficiency can lead to decreases of pyruvate to acetyl-CoA conversion, increasing intracellular lactate [19]. But data regarding thiamine deficiency in ESRD and RRT patients are controversial [20,21]. Case reports portray series of patients with several clinical manifestations, including Beriberi and Wernicke’s encephalopathy in non-alcoholic subjects, while other data do not support any evidence that there’s chronic reduction of thiamine levels in RRT patients [20,21]. In this scenario, patients submitted to a regular schedule of 15 h of dialysis per week could not suffer significant losses of thiamine through dialysate [22].

MMSE are probably the more broadly used test to evaluate cognitive status worldwide. The test consists in a sequence of questions grouped in seven categories, each one chosen in order to check a particular function as known temporal orientation (5 points), spatial orientation (5 points), word registry (3 points), attention and calculation (5 points), word recall (3 points), language (8 points) visual constructive capacity (1 point). The score goes from a minimum of 0 to a maximum of 30 points, corresponding to minimum and maximum level of cognitive capacity, usually used in elderly persons. The most frequently used cutoff is 24 points, although variations are proposed according to level of schooling. In this study the MMSE scores during thiamine supplementation, placebo use and in the control group did not vary in the testing month, either into or between the groups. The mean MMSE score levels were below the cutoff point for cognitive deficit in this population, despite the variation of ages of patients between the groups of study [10,11].

The results of this study suggest that 300 mg or 600 mg thiamine supplementation did not interfere with MMSE scores, but was not high at the beginning of supplementation.

However, there were significant improve of humor and in the perception of well-being, in a rapid period of administration of thiamine 600 mg. Data noticeable after the use of thiamine for a period of time larger than 3 months to a year, with no clear improve of cognitive function [22]. Studies with longer duration or the active form of the vitamin should be tested further, for more evident results [23,24]. The results suggest no cognitive interference for patients on chronic hemodialysis with 300 mg or 600 mg of thiamine for 1 month compared with placebo or control groups. Studies with longer duration or the active forms of the vitamin should be tested further.

Acknowledgment

This work was supported by Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM).

References

4. Callegari A, Barros EG, Veronese FV, Thomé FS. Malnourished patients

---

Table 2: Blood levels of lactate according to stages of the study.

<table>
<thead>
<tr>
<th>Groups</th>
<th>BASAL Lactate (mmol/L)</th>
<th>FINAL Lactate (mmol/L)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I Thiamine 300 mg</td>
<td>0.95 ± 0.07</td>
<td>0.90 ± 0.04</td>
<td>ns</td>
</tr>
<tr>
<td>Group II Thiamine 600 mg</td>
<td>0.94 ± 0.04</td>
<td>0.9 ± 0.04</td>
<td>ns</td>
</tr>
<tr>
<td>Group III Placebo</td>
<td>0.92 ± 0.07</td>
<td>0.95 ± 0.07</td>
<td>ns</td>
</tr>
<tr>
<td>Group IV Control</td>
<td>0.91 ± 0.09</td>
<td>0.92 ± 0.05</td>
<td>ns</td>
</tr>
<tr>
<td>p-value</td>
<td>ns</td>
<td>ns</td>
<td></td>
</tr>
</tbody>
</table>

Lactate, reference values (0.8 mmol/L to 2.0 mmol/L).


